Related to Transcriptome Yields Two Subtypes of Multiple Sclerosis

• NHGRI Fortifies Third-Generation Sequencing Development with $18M
  
• GSK and Genmab Focus on Subcutaneous Ofatumumab for Autoimmune Diseases
  
• Proximagen Gains Compound Hits for CXCR4 Target from Ligand Pharmaceuticals
  
• Aquapharm and Dundee University Team Up to Discover Marine-Derived Drugs against AD
  
• Novartis Gets FDA OK for MS Therapy and Makes Headway against Cushing Disease
  
• OpGen Closes $17M to Market Microbial Whole-Genome Analysis Platform
  
• DSP Nabs U.S. and Canadian Marketing Option to SanBio’s Phase I Cell Therapy
  
• Banyan Gets $26.3M to Develop Point-of-Care Diagnostic for Brain Injury
  
• Novartis Teams with Synthetic Genomics Vaccines to Develop Flu Seed Virus Banks
  
• Lundbeck Pays Genmab €7.5 Up Front in Deal Focused on CNS Diseases
  
• Cellectis Bioresearch Sets Up U.S. Subsidiary to Promote Targeted Genome Engineering Products
  
• Sanofi-Aventis’ Teriflunomide Comes Up Trumps in Two-Year Phase III MS Trial
  
• Biogen Idec and Genentech Tweak Anti-CD20 Alliance to Prevent Future Squabbles
  
• Index Pledges €10M to New Company’s Development of Peptide Candidates for CNS Diseases
  
• Merck KGaA Partners with European ScreeningPort on Multiple Sclerosis Research
  
• Pilot Phase of 1000 Genomes Project Identifies 8 Million New Genetic Variants
  
• Biovail Pays Acadia $8.75M to End Phase III Parkinson Disease Psychosis Drug Pact
  
• Novartis’ Afinitor Cleared by FDA for Treating SEGA Tumors in Tuberous Sclerosis
  
• Qualifying Therapeutic Discovery Project Doles Out More Than $17M
  
• Syntaxin Raises £18M to Progress Clostridium Neurotoxin-Based Secretion Inhibitor Pipeline